Tigecycline: In Community-Acquired Pneumonia

By McKeage Kate   Keating Gillian M.  

Drugs, Vol. 68, Iss. 18, 2008-01 ,pp. : 2633-2644

Adis International

Access to resources Recommend Favorite

Community‐Acquired Pneumonia

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 34, Iss. 3, 2004-09 ,pp. : 212-217

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-Effective Approaches to the Treatment of Community-Acquired Pneumonia in the Era of Resistance

By Kuti J.L.   Capitano B.   Nicolau D.P.  

PharmacoEconomics, Vol. 20, Iss. 8, 2002-08 ,pp. : 513-528

Adis International

Access to resources Recommend Favorite

Evolution of Antibiotic Use and Cost in Patients with Community-Acquired Pneumonia

By Sabbatani S.  

Clinical Drug Investigation, Vol. 22, Iss. 9, 2002-01 ,pp. : 601-608

Adis International

Access to resources Recommend Favorite

Efficacy, Onset of Action and Tolerability of Moxifloxacin in Patients with Community-Acquired Pneumonia: Results of a Postmarketing Surveillance Study

By Landen H.  

Clinical Drug Investigation, Vol. 21, Iss. 12, 2001-12 ,pp. : 801-811

Adis International

Access to resources Recommend Favorite